Last edition
News about "metabolic diseases "
Ascletis Receives FDA IND Clearance for Phase II ASC30 Diabetes Study
Ascletis has received US FDA IND clearance to initiate a 13-week phase-II, randomised, double-blind, placebo-controlled, multi-centre study evaluating the efficacy, safety and tolerability of its oral small-molecule GLP-1 candidate ASC30 in participants with diabetes, with enrollment expected to begin in the first quarter of 2026.
Metabolic Diseases | 05/01/2026 | By News Bureau
Eli Lilly and SanegeneBio Partner to Develop RNAi Therapies for Metabolic Diseases
SanegeneBio, a clinical-stage biotechnology company developing RNAi therapeutics, has entered into a global research and licensing collaboration with Eli Lilly and Company to advance RNAi candidates for metabolic diseases.
Metabolic Diseases. | 10/11/2025 | By Dineshwori | 262
Novo Nordisk to Acquire Akero Therapeutics Alongside Promising MASH Therapy Efruxifermin
Danish pharma giant Novo Nordisk has signed a definitive agreement to acquire Akero Therapeutics, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for serious metabolic diseases.
Metabolic Diseases | 10/10/2025 | By Dineshwori | 232
Sciwind Signs Global Licensing Deal with Verdiva for Metabolic Disease Portfolio
Sciwind has granted Verdiva the exclusive global rights to develop, manufacture and commercialize the partnered programs outside of greater China and South Korea.
Metabolic Diseases | 13/01/2025 | By Aishwarya | 406
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy